First-line treatment with the tyrosine kinase inhibitor (TKI) dacomitinib was associated with better overall survival (OS) than gefitinib among patients with EGFR-mutation–positive non–small-cell lung cancer (EGFR+ NSCLC), according to a final OS analysis from the...